Belsomra and Bupropion Interaction: What You Need to Know

How the Interaction Works at the Enzyme Level

Suvorexant is metabolized primarily by cytochrome P450 3A4 (CYP3A4), with secondary contributions from CYP2C19 and CYP2D6. Bupropion and its active metabolite hydroxybupropion are potent inhibitors of CYP2D6, with inhibition constants (Ki) in the low micromolar range. Because CYP2D6 handles a minority of suvorexant clearance, the net effect of adding bupropion is a modest increase in suvorexant area under the curve (AUC), estimated at 15 to 25% based on pharmacokinetic modeling from the FDA clinical pharmacology review for suvorexant.

That number is far smaller than the effect of strong CYP3A4 inhibitors. Ketoconazole, a strong CYP3A4 blocker, increased suvorexant AUC by roughly 179% in a dedicated crossover study (N=24), prompting the FDA to halve the maximum recommended dose to 10 mg when any moderate or strong CYP3A4 inhibitor is on board. Bupropion does not meaningfully inhibit CYP3A4. So the interaction between these two drugs is real but secondary, driven by the CYP2D6 pathway alone.

A separate pharmacodynamic layer exists. Both drugs act on the central nervous system. Suvorexant blocks orexin receptors to promote sleep. Bupropion raises norepinephrine and dopamine tone to treat depression. Their CNS effects are pharmacologically opposing in some respects, yet additive sedation has been reported in post-marketing surveillance when any sleep-promoting agent is combined with a psychotropic that alters arousal pathways.

Severity Rating and What Databases Say

Drug interaction databases classify the suvorexant-bupropion pair as moderate. Lexicomp rates it category C (monitor therapy), and Clinical Pharmacology assigns a severity rating of moderate with a documentation level of fair. The interaction is not listed as contraindicated by any major reference.

The FDA label for Belsomra states that the dose "should not exceed 10 mg" in patients taking concomitant moderate CYP3A4 inhibitors, and it advises caution with any drug that "may increase suvorexant exposure." Bupropion falls into the caution category rather than the explicit dose-cap category, because its inhibitory action targets CYP2D6, not CYP3A4. Still, the cumulative effect of even modest AUC increases on a drug with a 12-hour half-life can produce clinically noticeable next-day drowsiness, especially in older adults or patients with hepatic impairment.

No dedicated drug-drug interaction study of suvorexant plus bupropion has been published in a peer-reviewed journal as of May 2026. The clinical guidance below draws on the individual FDA labels, physiologically based pharmacokinetic (PBPK) modeling from the suvorexant NDA review, and extrapolation from studies of CYP2D6-mediated interactions with other substrates.

Who Is Most Likely to Be Affected

Not every patient taking both drugs will notice a difference. Three populations face higher risk of clinically meaningful changes in suvorexant exposure.

CYP2D6 poor metabolizers. Roughly 6 to 10% of Caucasians and 1 to 2% of East Asian populations carry nonfunctional CYP2D6 alleles, according to data from the Clinical Pharmacogenetics Implementation Consortium. In these patients, bupropion cannot further inhibit an enzyme that is already inactive, but the baseline contribution of CYP2D6 to suvorexant clearance is already zero. Their suvorexant levels may already run 10 to 15% higher than extensive metabolizers, so the clinical margin is thinner.

Patients on concurrent moderate CYP3A4 inhibitors. A patient taking diltiazem (a moderate CYP3A4 inhibitor) plus bupropion would experience dual-pathway inhibition of suvorexant metabolism. The suvorexant label already mandates a 10 mg dose cap with moderate CYP3A4 inhibitors; adding bupropion on top may push effective exposure closer to the range seen with strong CYP3A4 inhibition.

Older adults. The suvorexant AUC is approximately 25% higher in women and in adults aged 65 and older compared with younger men, per the FDA clinical pharmacology review. A 70-year-old woman on both drugs could experience a compounded elevation in drug exposure.

Seizure Threshold Considerations

Bupropion carries a dose-dependent seizure risk. The FDA label for bupropion reports a seizure incidence of approximately 0.4% at doses up to 450 mg/day of the immediate-release formulation, compared to 0.1% in the general population. This risk increases sharply above 450 mg/day and in patients with predisposing conditions such as eating disorders, abrupt alcohol or benzodiazepine withdrawal, or a prior seizure history.

Suvorexant itself is not associated with seizure induction. Orexin receptor antagonism does not lower seizure threshold in animal models, and seizures were not identified as an adverse event in the phase III program (studies 028 and 029, combined N=3,291). The concern with this combination is indirect: excessive sedation from elevated suvorexant levels could mask early warning signs of a seizure prodrome, or a patient might skip bupropion doses erratically, which itself raises seizure risk.

The practical takeaway is straightforward. This is not a seizure-provoking combination per se. Clinicians should confirm bupropion is dosed within label limits and that the patient has no independent seizure risk factors before co-prescribing.

Dose Adjustment and Prescribing Guidance

The evidence supports a conservative starting strategy rather than avoidance of the combination.

Step 1: Start suvorexant low. Begin at 5 mg nightly. The FDA-approved dose range is 5 to 20 mg, and the label recommends 10 mg as the typical starting dose. Dropping to 5 mg provides a safety buffer when a CYP2D6 inhibitor is present.

Step 2: Hold for 7 to 14 days. Bupropion reaches steady-state inhibition of CYP2D6 within one to two weeks. The interaction will be maximal at that point, so reassess sedation and next-day impairment after this interval.

Step 3: Titrate based on response. If 5 mg is inadequate and the patient denies next-day drowsiness, somnolence, or impaired driving ability, increase to 10 mg. Going above 10 mg in the presence of any CYP inhibitor is not recommended by the Belsomra prescribing information.

Step 4: Audit the full medication list. If the patient also takes a moderate CYP3A4 inhibitor (erythromycin, fluconazole, diltiazem, verapamil, grapefruit juice in large quantities), the suvorexant dose must stay at 10 mg or below regardless, and closer monitoring is warranted. Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) make suvorexant use inadvisable at any dose per the label.

Monitoring Parameters for the Combination

Clinicians and patients should track four endpoints during co-administration.

Next-day somnolence. The most common adverse effect of suvorexant in clinical trials was somnolence, reported in 7% of patients on 15 to 20 mg versus 3% on placebo in study 028 (Herring et al., 2012, N=1,021). Higher effective exposure from the bupropion interaction may shift a patient from the 10 mg efficacy profile toward the 15 to 20 mg side-effect profile.

Complex sleep behaviors. The suvorexant label carries a warning for sleep-walking, sleep-driving, and other activities performed while not fully awake. These events are rare (reported incidence <1%) but serious. Any new onset of parasomnia-like behavior after adding bupropion should prompt immediate discontinuation of suvorexant.

Mood and suicidality. Bupropion's black-box warning covers increased suicidal thinking in patients under 25. Adding a sleep agent does not change this risk directly, but disrupted sleep architecture can worsen depressive symptoms. Ensure the patient has a follow-up appointment within two weeks of any medication change.

Driving ability. The FDA issued a safety communication in 2014 noting that suvorexant 20 mg impaired next-morning driving ability in some subjects. Patients should be counseled to allow at least 7 hours of sleep opportunity and to avoid driving until they know how the combination affects them.

What About Switching to a Different Sleep Agent?

If the interaction produces unacceptable sedation or the prescriber prefers to avoid the pharmacokinetic overlap entirely, alternatives exist.

Lemborexant (Dayvigo), the other approved orexin receptor antagonist, is metabolized primarily by CYP3A4 with minimal CYP2D6 involvement, so the bupropion interaction profile is similar or slightly more favorable. Low-dose doxepin (Silenor, 3 to 6 mg) is metabolized by CYP2D6 and CYP2C19, making it a poor alternative in this specific scenario because bupropion would inhibit its clearance more directly.

Melatonin receptor agonists such as ramelteon (Rozerem) are metabolized by CYP1A2 and CYP2C, neither of which bupropion inhibits meaningfully. Ramelteon may be the cleanest pharmacokinetic option for a patient on bupropion who needs a non-benzodiazepine sleep aid, though its efficacy profile differs from orexin antagonists. A Cochrane review of ramelteon found modest reductions in sleep latency (weighted mean difference of approximately 9 minutes versus placebo).

Patient Counseling Points

Patients prescribed both medications need five pieces of information.

Take suvorexant within 30 minutes of bedtime and only if you can remain in bed for at least 7 hours. Do not take it with or immediately after a high-fat meal, which delays absorption by approximately 1.5 hours per the FDA label.

Avoid alcohol entirely while on this combination. Alcohol is a CNS depressant that amplifies sedation and independently lowers seizure threshold, compounding both concerns of the interaction.

Report any episodes of doing things during sleep that you do not remember. This includes sleepwalking, preparing food, making phone calls, or driving.

Do not stop bupropion abruptly without medical guidance. While bupropion does not cause classical withdrawal, abrupt discontinuation can destabilize mood and paradoxically alter sleep quality, creating a moving target for suvorexant dosing.

Keep all follow-up appointments. The first two weeks after starting or changing the dose of either drug are the highest-risk window for adverse effects from the interaction.

Pharmacokinetic Summary Table

Suvorexant is 99.5% protein-bound with a volume of distribution of approximately 49 liters per the clinical pharmacology review. Bupropion is 84% protein-bound. Neither drug is likely to displace the other at therapeutic concentrations, so protein-binding competition is not a meaningful contributor to this interaction.

The time to peak concentration (Tmax) for suvorexant is 2 hours (fasted) and the elimination half-life is 12 hours. Bupropion's Tmax is about 2 hours for the immediate-release formulation, and its primary active metabolite hydroxybupropion has a half-life of approximately 20 hours. The slow accumulation of hydroxybupropion means that CYP2D6 inhibition builds over the first week of therapy, so the interaction may not be apparent on day one.

Renal impairment does not significantly alter suvorexant pharmacokinetics. Hepatic impairment does. In patients with moderate hepatic impairment (Child-Pugh B), suvorexant AUC increased by approximately 2-fold in the NDA review data. Suvorexant is not recommended in patients with severe hepatic impairment (Child-Pugh C). Adding bupropion to a patient with even mild hepatic dysfunction warrants extra caution and possibly a 5 mg dose cap for suvorexant.

Clinical Bottom Line

The suvorexant-bupropion combination is manageable but not trivial. Start suvorexant at 5 mg, reassess at 7 to 14 days, cap at 10 mg, and monitor for next-day drowsiness and complex sleep behaviors. Patients with hepatic impairment, CYP2D6 poor-metabolizer status, or concurrent CYP3A4 inhibitors require the most conservative dosing.